Identification of coinfections by viral and bacterial pathogens in covid-19 hospitalized patients in peru: Molecular diagnosis and clinical characteristics

• Autores: Pérez-Lazo, Giancarlo, Silva-Caso, Wilmer, Del Valle-Mendoza, Juana, Morales-Moreno, Adriana, Ballena-López, José, Soto-Febres, Fernando, Martins-Luna, Johanna, Carrillo-Ng, Hugo, Del Valle, Luís J., Kym, Sungmin, Aguilar-Luis, Miguel Angel, Peña-Tuesta, Issac, Tinco-Valdez, Carmen, Illescas, Luis Ricardo
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Universidad Peruana de Ciencias Aplicadas
• Repositorio: UPC-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorioacademico.upc.edu.pe:10757/658426
• Enlace del recurso: http://hdl.handle.net/10757/658426
• Nivel de acceso: acceso abierto
• Materia: Antibiotics; Coinfections; COVID-19

The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSV-B/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae.